Chimerix, Inc. in brief
Chimerix, Inc. is an unlisted company in the Biotechnology industry, based in North Carolina, USA. It was founded in 2000. In the year to Dec 2021 it had sales of $1 M and a net loss of $173 M. It employs about 87 people.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Chimerix, Inc.
Chimerix is a Biotechnology company committed to developing medicines to meaningfully improve the probability of survival for people facing deadly diseases. The company annual revenue is 5.37 million USD and 43 employees as on 2020. The headquarters is in USA.
Chimerix, Inc. timeline
- 2000
- 🏁· approximateFounded
- 2013
- 🔔· approximateInitial public offering on Nasdaq
Events of Chimerix, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Chimerix, Inc.
- Acquisitions and changes
- No longer listed: ticker CMRX is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #3,578 (Jan 2020) · #2,942 (Jan 2021) · #3,227 (Jan 2022) · #3,875 (Dec 2022) · #4,206 (Jul 2023) · #3,800 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -17300.0%
- Operating margin
- —
- Return on equity
- -254.4%
- Liabilities / assets
- 32.0%
- Revenue per employee
- $11 K
- Profit per employee
- $-2.0 M
Annual results
- Revenue
- $1 M
- Operating income
- —
- Net income
- $-173 M
Dec-2021 ending year
Balance sheet
- Total assets
- $100 M
- Total liabilities
- $32 M
- Total equity
- $68 M
Dec-2021 ending year
Markets and events: Chimerix, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-04-17 23:50 UTC, code D, resumed 04:00 UTC
- 2025-03-05 11:55 UTC, code T3, resumed 12:30 UTC
Fails to deliver
- : 124,944 shares at $8.54
- : 325,644 shares at $8.55
- : 93 shares at $8.52
- : 64 shares at $8.51
- : 241,701 shares at $8.53
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Lobbying by Chimerix, Inc.#
$170 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues.
- Health Issues3 reports
Lobbying firms hired in 2022
BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ /THE DASCHLE GROUP $170 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $170 K | — | 4 |
| 2021 | $190 K | — | 4 |
| 2020 | $200 K | — | 4 |
| 2019 | $140 K | — | 7 |
| 2018 | $130 K | — | 7 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Chimerix, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Chimerix, Inc. compares in Biotechnology
- Revenue$1 M · higher than 24% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Chimerix, Inc.🇺🇸 | $86 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- Dec-2021 ending year
- Balance sheet:
- Dec-2021 ending year
- Employees:
- As on 2021
- Profile updated:
- Nov 14, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Chimerix, Inc.? Verify and update this profile — free
Show Chimerix, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.